PDAP1
gene geneOn this page
Also known as PAP1PAPHASPP28
Summary
PDAP1 (PDGFA associated protein 1, HGNC:14634) is a protein-coding gene on chromosome 7q22.1, encoding 28 kDa heat- and acid-stable phosphoprotein (Q13442). Enhances PDGFA-stimulated cell growth in fibroblasts, but inhibits the mitogenic effect of PDGFB. It is a common-essential gene (DepMap: required in 95.2% of cancer cell lines).
The protein encoded by this gene is a phosphoprotein that may upregulate the PDGFA-stimulated growth of fibroblasts and also downregulate the mitogenicity of PDGFB. The encoded protein in rodents has been shown to bind PDGFA with a low affinity.
Source: NCBI Gene 11333 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 22 total
- Expression (HPA): Low tissue specificity — highest in spinal cord, ventral spinal cord, midbrain
- GTEx eGene: eQTL in 9 tissues, sQTL in 3 (q < 0.05)
- Cancer dependency (DepMap): dependent in 95.2% of screened cell lines (common-essential)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.93 (unconstrained)
- MANE Select transcript:
NM_014891
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:14634 |
| Approved symbol | PDAP1 |
| Name | PDGFA associated protein 1 |
| Location | 7q22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | PAP1, PAP, HASPP28 |
| Ensembl gene | ENSG00000106244 |
| Ensembl biotype | protein_coding |
| OMIM | 607075 |
| Entrez | 11333 |
Gene structure
Transcript identifiers
Ensembl transcripts: 38 — 23 protein_coding, 13 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined
MANE Select: ENST00000350498
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 3: 2, TSL 5: 2
ENST00000350498, ENST00000426447, ENST00000488214, ENST00000496335, ENST00000626285, ENST00000856632, ENST00000856633, ENST00000926895, ENST00000926896, ENST00000926897, ENST00000926898, ENST00000977178, ENST00000977179, ENST00000977180, ENST00001030474, ENST00001030476, ENST00001030478, ENST00001030482, ENST00001086401, ENST00001086402, ENST00001086403, ENST00001086405, ENST00001086409, ENST00001086415, ENST00001086416, ENST00001086417, ENST00001086418, ENST00001086419, ENST00001091001, ENST00001091002, ENST00001091003, ENST00001091004, ENST00001091005, ENST00001091006, ENST00001091007, ENST00001113624, ENST00001128066, ENST00001142155
RefSeq mRNA: 1 — MANE Select: NM_014891
NM_014891
CCDS: CCDS5662
Canonical transcript exons
ENST00000350498 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000708078 | 99403398 | 99403505 |
| ENSE00000824720 | 99404862 | 99404953 |
| ENSE00001104225 | 99394673 | 99396740 |
| ENSE00001289631 | 99408536 | 99408597 |
| ENSE00003470523 | 99397862 | 99398013 |
| ENSE00003513823 | 99400303 | 99400424 |
Expression profiles
Bgee: expression breadth ubiquitous, 283 present calls, max score 98.51.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 101.9407 / max 997.1908, expressed in 1825 samples.
Highest expression (Bgee): gastrocnemius, muscle of leg, mucosa of stomach, lower esophagus muscularis layer, lower esophagus.
Genetic regulation across tissues (GTEx eQTL / sQTL)
PDAP1 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 9 tissues and its splicing (sQTL) in 3 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
12 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Testis | sqtl | 4.8e-18 | -0.87 | 7:99383134:C:T |
| Skin Sun Exposed Lower leg | sqtl | 7.8e-07 | -1.06 | 7:99439732:G:A |
| Testis | eqtl | 9.4e-03 | -0.23 | 7:98983889:C:A |
| Cells Cultured fibroblasts | eqtl | 1.3e-02 | -0.07 | 7:99427277:C:T |
| Colon Sigmoid | eqtl | 1.5e-02 | -0.11 | 7:99260544:T:C |
| Whole Blood | eqtl | 1.8e-02 | -0.10 | 7:99387773:A:G |
| Nerve Tibial | eqtl | 2.4e-02 | +0.07 | 7:100002782:A:T |
| Skin Not Sun Exposed Suprapubic | eqtl | 3.3e-02 | +0.31 | 7:99166594:T:C |
| Skin Sun Exposed Lower leg | eqtl | 4.2e-02 | +0.21 | 7:98989800:C:A |
| Thyroid | sqtl | 4.3e-02 | +0.38 | 7:99384417:CT:C |
| Heart Left Ventricle | eqtl | 4.3e-02 | +0.09 | 7:98443657:T:C |
| Artery Tibial | eqtl | 4.9e-02 | -0.12 | 7:99094891:G:A |
FANTOM5 promoters
2 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 85101 | 100.4681 | 1825 |
| 85102 | 1.4726 | 1012 |
Top tissues by expression
showing 100 of 291 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| gastrocnemius | UBERON:0001388 | 98.51 | gold quality |
| muscle of leg | UBERON:0001383 | 98.38 | gold quality |
| mucosa of stomach | UBERON:0001199 | 97.99 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 97.93 | gold quality |
| lower esophagus | UBERON:0013473 | 97.92 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 97.85 | gold quality |
| popliteal artery | UBERON:0002250 | 97.81 | gold quality |
| tibial artery | UBERON:0007610 | 97.81 | gold quality |
| sural nerve | UBERON:0015488 | 97.76 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 97.76 | gold quality |
| thoracic aorta | UBERON:0001515 | 97.71 | gold quality |
| ascending aorta | UBERON:0001496 | 97.70 | gold quality |
| left coronary artery | UBERON:0001626 | 97.70 | gold quality |
| aorta | UBERON:0000947 | 97.69 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 97.68 | gold quality |
| right coronary artery | UBERON:0001625 | 97.63 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 97.63 | gold quality |
| cortical plate | UBERON:0005343 | 97.62 | gold quality |
| ganglionic eminence | UBERON:0004023 | 97.60 | gold quality |
| tibial nerve | UBERON:0001323 | 97.56 | gold quality |
| skin of leg | UBERON:0001511 | 97.56 | gold quality |
| stromal cell of endometrium | CL:0002255 | 97.55 | gold quality |
| right atrium auricular region | UBERON:0006631 | 97.39 | gold quality |
| monocyte | CL:0000576 | 97.37 | gold quality |
| skin of abdomen | UBERON:0001416 | 97.37 | gold quality |
| body of uterus | UBERON:0009853 | 97.36 | gold quality |
| calcaneal tendon | UBERON:0003701 | 97.33 | gold quality |
| ectocervix | UBERON:0012249 | 97.26 | gold quality |
| minor salivary gland | UBERON:0001830 | 97.22 | gold quality |
| left adrenal gland | UBERON:0001234 | 97.21 | gold quality |
| endometrium epithelium | UBERON:0004811 | 97.21 | gold quality |
| left ovary | UBERON:0002119 | 97.19 | gold quality |
| right lung | UBERON:0002167 | 97.19 | gold quality |
| esophagus | UBERON:0001043 | 97.15 | gold quality |
| right ovary | UBERON:0002118 | 97.15 | gold quality |
| right adrenal gland | UBERON:0001233 | 97.13 | gold quality |
| left uterine tube | UBERON:0001303 | 97.13 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 97.13 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 97.10 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 97.08 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 97.08 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 97.07 | gold quality |
| body of pancreas | UBERON:0001150 | 97.04 | gold quality |
| body of stomach | UBERON:0001161 | 97.04 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 97.01 | gold quality |
| endocervix | UBERON:0000458 | 96.97 | gold quality |
| ventricular zone | UBERON:0003053 | 96.95 | gold quality |
| mononuclear cell | CL:0000842 | 96.91 | gold quality |
| transverse colon | UBERON:0001157 | 96.91 | gold quality |
| coronary artery | UBERON:0001621 | 96.90 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 96.90 | gold quality |
| leukocyte | CL:0000738 | 96.79 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 96.76 | gold quality |
| metanephros cortex | UBERON:0010533 | 96.68 | gold quality |
| granulocyte | CL:0000094 | 96.66 | gold quality |
| gall bladder | UBERON:0002110 | 96.63 | gold quality |
| apex of heart | UBERON:0002098 | 96.61 | gold quality |
| right frontal lobe | UBERON:0002810 | 96.59 | gold quality |
| esophagus mucosa | UBERON:0002469 | 96.56 | gold quality |
| omental fat pad | UBERON:0010414 | 96.54 | gold quality |
| peritoneum | UBERON:0002358 | 96.52 | gold quality |
| muscle organ | UBERON:0001630 | 96.51 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 96.51 | gold quality |
| rectum | UBERON:0001052 | 96.47 | gold quality |
| islet of Langerhans | UBERON:0000006 | 96.41 | gold quality |
| gluteal muscle | UBERON:0002000 | 96.40 | gold quality |
| adenohypophysis | UBERON:0002196 | 96.34 | gold quality |
| cardiac atrium | UBERON:0002081 | 96.26 | gold quality |
| cingulate cortex | UBERON:0003027 | 96.26 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 96.25 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 96.20 | gold quality |
| heart left ventricle | UBERON:0002084 | 96.19 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 96.19 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 96.16 | gold quality |
| triceps brachii | UBERON:0001509 | 96.15 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 96.15 | gold quality |
| adrenal gland | UBERON:0002369 | 96.13 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 96.11 | gold quality |
| cerebellar cortex | UBERON:0002129 | 96.08 | gold quality |
| adrenal cortex | UBERON:0001235 | 96.07 | gold quality |
| upper lobe of lung | UBERON:0008948 | 96.04 | gold quality |
| thyroid gland | UBERON:0002046 | 95.99 | gold quality |
| prefrontal cortex | UBERON:0000451 | 95.93 | gold quality |
| cardiac ventricle | UBERON:0002082 | 95.87 | gold quality |
| stomach | UBERON:0000945 | 95.63 | gold quality |
| small intestine | UBERON:0002108 | 95.60 | gold quality |
| heart | UBERON:0000948 | 95.55 | gold quality |
| sigmoid colon | UBERON:0001159 | 95.40 | gold quality |
| spleen | UBERON:0002106 | 95.40 | gold quality |
| amygdala | UBERON:0001876 | 95.33 | gold quality |
| left testis | UBERON:0004533 | 95.33 | gold quality |
| right testis | UBERON:0004534 | 95.29 | gold quality |
| right uterine tube | UBERON:0001302 | 95.26 | gold quality |
| pancreas | UBERON:0001264 | 95.21 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 95.20 | gold quality |
| tendon | UBERON:0000043 | 95.19 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 95.16 | gold quality |
| spinal cord | UBERON:0002240 | 95.15 | gold quality |
| embryo | UBERON:0000922 | 95.12 | gold quality |
| cerebellum | UBERON:0002037 | 95.03 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 13.00 |
HPA expression
RNA tissue specificity: Low tissue specificity
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Spinal cord | tissue | 118.2 | |
| Midbrain | tissue | 111.9 | |
| Thalamus | tissue | 108.5 | |
| Hippocampal formation | tissue | 107.7 | |
| Pons | tissue | 106.2 | |
| Corpus callosum | tissue | 105.2 | |
| Medulla oblongata | tissue | 104.7 | |
| Superior colliculi | tissue | 104.2 | |
| Cerebral cortex | tissue | 102.8 | medium |
| Motor cortex | tissue | 102.8 | |
| Somatosensory cortex | tissue | 99.7 | |
| Prefrontal cortex | tissue | 98.5 | |
| Substantia nigra | tissue | 98.5 | |
| Skeletal muscle | tissue | 98.3 | high |
| Occipital cortex | tissue | 96.1 | |
| Putamen | tissue | 94.4 | |
| Retrosplenial and cingulate cortex | tissue | 91.6 | |
| Entorhinal cortex | tissue | 91.4 | |
| Periaqueductal gray | tissue | 91.1 | |
| Temporal cortex | tissue | 90.2 | |
| Hypothalamus | tissue | 88.9 | |
| Retrosplenial cortex | tissue | 86.3 | |
| Insular cortex | tissue | 85.7 | |
| Septum | tissue | 84.6 | |
| Basal ganglia | tissue | 83.6 | low |
| Amygdala | tissue | 83.6 | |
| Ventral forebrain | tissue | 81.7 | |
| Olfactory bulb | tissue | 79.1 | |
| Cerebellum | tissue | 76.3 | high |
| Tongue | tissue | 55.8 | |
| Frontal cortex | tissue | 45.6 | |
| Caudate putamen | tissue | 38.3 | |
| Locus coeruleus | tissue | 32.4 | |
| Hippocampus | tissue | 27.6 | medium |
| Choroid plexus | tissue | 27.3 | |
| Postcentral gyrus | tissue | 27.3 | |
| Heart muscle | tissue | 24.4 | medium |
| Nucleus accumbens | tissue | 24.4 | |
| Vagina | tissue | 24.2 | medium |
| Thymus | tissue | 23.8 | |
| Ovary | tissue | 22.8 | high |
| Adipose tissue | tissue | 22.2 | low |
| Bone marrow | tissue | 21.8 | medium |
| Appendix | tissue | 21.3 | high |
| Retina | tissue | 21.2 | |
| Parathyroid gland | tissue | 21.2 | medium |
| Tonsil | tissue | 21.0 | high |
| Pituitary gland | tissue | 20.7 | |
| Seminal vesicle | tissue | 19.7 | medium |
| Smooth muscle | tissue | 19.7 | medium |
| Urinary bladder | tissue | 19.0 | medium |
| Colon | tissue | 18.6 | high |
| Salivary gland | tissue | 18.4 | medium |
| Placenta | tissue | 18.1 | medium |
| Skin 1 | tissue | 18.0 | high |
| Lymph node | tissue | 17.7 | high |
| Liver | tissue | 17.7 | medium |
| Prostate | tissue | 17.6 | medium |
| Adrenal gland | tissue | 17.6 | high |
| Stomach 1 | tissue | 17.4 | medium |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Ventral spinal cord (118.2), Dorsal hippocampus (107.7), White matter (105.2), Dorsal spinal cord (102.9), Ventral hippocampus (96.5).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting PDAP1 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 125 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-4673 | 100.00 | 66.64 | 1490 |
| HSA-MIR-3120-5P | 100.00 | 65.56 | 965 |
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-4533 | 100.00 | 69.48 | 2758 |
| HSA-MIR-181A-5P | 99.99 | 72.96 | 2995 |
| HSA-MIR-181B-5P | 99.99 | 72.97 | 2996 |
| HSA-MIR-181C-5P | 99.99 | 72.95 | 2996 |
| HSA-MIR-181D-5P | 99.99 | 73.04 | 2997 |
| HSA-MIR-150-5P | 99.99 | 66.69 | 1976 |
| HSA-MIR-4645-5P | 99.98 | 65.81 | 1284 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-548N | 99.98 | 71.94 | 4170 |
| HSA-MIR-548P | 99.98 | 72.25 | 3784 |
| HSA-MIR-6888-3P | 99.97 | 65.95 | 1170 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-548AJ-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548X-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-185-3P | 99.95 | 67.01 | 1743 |
| HSA-MIR-545-3P | 99.95 | 70.74 | 2783 |
| HSA-MIR-381-3P | 99.93 | 71.87 | 2854 |
| HSA-MIR-300 | 99.92 | 71.76 | 2856 |
| HSA-MIR-15A-5P | 99.90 | 72.80 | 2787 |
| HSA-MIR-15B-5P | 99.90 | 72.78 | 2798 |
| HSA-MIR-16-5P | 99.90 | 72.80 | 2780 |
Functional genomics
gnomAD constraint: pLI 0.00355, LOEUF 0.934, missense Z 1.72 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000350498 — one region, missense o/e 0.65.
DepMap (CRISPR cell-line fitness): dependent in 95.2% of screened cell lines, common-essential.
Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): SNU-840 (-2.517), F-36P (-2.248), GSU (-2.14), KELLY (-2.095), MFE-280 (-2.05), AsPC-1 (-1.975), B-CPAP (-1.856), NCI-H82 (-1.828), IMR-32 (-1.747), KARPAS-422 (-1.734), NMC-G1 (-1.731), SNU-685 (-1.729), RD-ES (-1.721), OCI-LY-19 (-1.72), NB-4 (-1.718).
Literature-anchored findings (GeneRIF, showing 3)
- PDAP-1 as an effecter of PDGF signaling in glioma cells (PMID:27448842)
- AG1024+U0126 acted synergistically to downregulate “synergy” genes, especially STAT6 and PDAP1, which displayed significant expression codependency and a common expression pattern linked with other key “synergy” genes, supporting their predicted role in an STAT6-ERK-nuclear factor kappa beta (NF-kappaB) network. Daunorubicin and PDAP1 loss were synergistic, so PDAP1 is important for the response to this anthracycline. (PMID:29656114)
- RFX transcription factors control a miR-150/PDAP1 axis that restrains the proliferation of human T cells. (PMID:35143476)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | pdap1b | ENSDARG00000002967 |
| mus_musculus | Pdap1 | ENSMUSG00000029623 |
| rattus_norvegicus | Pdap1 | ENSRNOG00000000990 |
| drosophila_melanogaster | CG11444 | FBGN0029715 |
| drosophila_melanogaster | CG4438 | FBGN0032115 |
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:2448536) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 7 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| abnormal B cell physiology | 1 |
| abnormal somatic hypermutation frequency | 1 |
| abnormal class switch recombination | 1 |
| abnormal mitochondrial physiology | 1 |
| decreased germinal center B cell number | 1 |
| decreased mature B cell number | 1 |
| increased B cell apoptosis | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Dictyostelium discoideum | Q556U5 | 46.5% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| ARPC1A | protein-coding | 10552 |
| MIR12119 | ncRNA | 113219453 |
| MYH16 | protein-coding | 84176 |
| BUD31 | protein-coding | 8896 |
| ARPC1B | protein-coding | 10095 |
| KPNA7 | protein-coding | 402569 |
| SMURF1 | protein-coding | 57154 |
| ATP5MF-PTCD1 | protein-coding | 100526740 |
| PTCD1 | protein-coding | 26024 |
| CPSF4 | protein-coding | 10898 |
| ATP5MF | protein-coding | 9551 |
Protein
Protein identifiers
28 kDa heat- and acid-stable phosphoprotein — Q13442 (reviewed: Q13442)
Alternative names: PDGF-associated protein, PDGFA-associated protein 1
All UniProt accessions (2): F8WBW6, Q13442
UniProt curated annotations — full annotation on UniProt →
Function. Enhances PDGFA-stimulated cell growth in fibroblasts, but inhibits the mitogenic effect of PDGFB.
Similarity. Belongs to the PDAP1 family.
RefSeq proteins (1): NP_055706* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR019380 | Casein_kinase_sb_PP28 | Domain |
| IPR039876 | HAP28 | Family |
Pfam: PF10252
UniProt features (27 total): modified residue 11, sequence conflict 7, compositionally biased region 5, region of interest 2, chain 1, cross-link 1
Structure
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q13442-F1 | 77.09 | 0.32 |
Human Protein Atlas
Protein class: Predicted intracellular proteins, Plasma proteins, Cancer-related genes, Mutated cancer genes, Essential proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): cytosol; plasma membrane
Antibody reliability (HPA): IH approved · IF enhanced
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (12)
| Type | Positions |
|---|---|
| Phosphoserine | 57, 60, 63, 176, 178, 19 |
| Phosphotyrosine | 70 |
| N6-methyllysine | 126 |
| N6-acetyllysine | 132, 164 |
| Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo2) | 52 |
| Phosphothreonine | 18 |
Function
Pathways and Gene Ontology
Reactome pathways
1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
3 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-6798695 | Neutrophil degranulation | curated |
| R-HSA-168256 | Immune System | — |
| R-HSA-168249 | Innate Immune System | — |
MSigDB gene sets: 223 (showing top):
MORF_MTA1, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, GCANCTGNY_MYOD_Q6, MORF_UBE2I, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, CAGCTG_AP4_Q5, CEBPB_01, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, MARTINEZ_RB1_TARGETS_UP, MODULE_120, MORF_SKP1A, CEBP_Q2, MORF_RAF1
GO Biological Process (1): signal transduction (GO:0007165)
GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)
GO Cellular Component (4): extracellular region (GO:0005576), cytosol (GO:0005829), plasma membrane (GO:0005886), ficolin-1-rich granule lumen (GO:1904813)
Reactome top-level categories
2 top-level categories:
| Category | Pathways |
|---|---|
| Innate Immune System | 1 |
| Immune System | 1 |
GO top-level categories
13 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| cell communication | 1 |
| cellular process | 1 |
| signaling | 1 |
| regulation of cellular process | 1 |
| cellular response to stimulus | 1 |
| nucleic acid binding | 1 |
| binding | 1 |
| cytoplasm | 1 |
| membrane | 1 |
| cell periphery | 1 |
| intracellular organelle lumen | 1 |
| ficolin-1-rich granule | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 7 annotations. The rest are phylogenetic / computational / electronic (IEA).
3 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| cytosol | CC | direct assay |
| plasma membrane | CC | direct assay |
| RNA binding | MF | high-throughput assay |
Protein interactions and networks
STRING
showing 15 of 1,372 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| PDAP1 | PDGFA | P04085 | 773 |
| PDAP1 | PDGFB | P01127 | 642 |
| PDAP1 | C8orf88 | P0DMB2 | 499 |
| PDAP1 | RFX8 | Q6ZV50 | 458 |
| PDAP1 | KCTD6 | Q8NC69 | 434 |
| PDAP1 | CDC42EP4 | Q9H3Q1 | 433 |
| PDAP1 | RCN2 | Q14257 | 427 |
| PDAP1 | ZSCAN29 | Q8IWY8 | 398 |
| PDAP1 | RMND1 | Q9NWS8 | 393 |
| PDAP1 | OR5I1 | Q13606 | 382 |
| PDAP1 | DPY19L4 | Q7Z388 | 380 |
| PDAP1 | RBM7 | Q9Y580 | 371 |
| PDAP1 | CAPZA2 | P47755 | 370 |
| PDAP1 | TBCK | Q8TEA7 | 366 |
| PDAP1 | ZFYVE21 | Q9BQ24 | 346 |
IntAct
Human interaction partners of PDAP1 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
4 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| PELI1 | physical association | 0.560 | 3 |
| KLHL36 | physical association | 0.500 | 1 |
| CSNK2A1 | phosphorylation reaction | 0.440 | 1 |
| FZD7 | physical association | 0.370 | 1 |
BioGRID (142 interactions; top human partners by supporting records): EIF1AX (Cross-Linking-MS (XL-MS); 2 records), HSPA1A (Proximity Label-MS; 2 records), LMNA (Co-fractionation; 2 records), RPS11 (Affinity Capture-MS; 2 records), ABCE1 (Cross-Linking-MS (XL-MS)), APP (Reconstituted Complex), ASAP2 (Co-fractionation), ASUN (Co-fractionation), BAD (Proximity Label-MS), BAG1 (Co-fractionation), BAP1 (Affinity Capture-MS), BICD2 (Proximity Label-MS), CD74 (Affinity Capture-MS), CDH1 (Proximity Label-MS), CEBPA (Protein-peptide)
Disease & clinical
Genetic variants
Variant evidence for PDAP1: 22 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.
ClinVar
22 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 14 |
| Likely benign | 0 |
| Benign | 2 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 33 predictions of 503):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 7:99397870 | donor_gain | 1.0000 | |
| 7:99400310 | donor_gain | 1.0000 | |
| 7:99403396–99403397 | donor_loss | 1.0000 | 5 |
| 7:99397860–99397861 | donor_loss | 0.9900 | 5 |
| 7:99397865 | donor_gain | 0.9900 | |
| 7:99398014–99398016 | acceptor_gain | 0.9900 | 2 |
| 7:99398014–99398015 | acceptor_loss | 0.9900 | 5 |
| 7:99400301–99400302 | donor_loss | 0.9900 | 6 |
| 7:99400425–99400426 | acceptor_loss | 0.9900 | 6 |
| 7:99400300 | donor_loss | 0.9800 |
AlphaMissense
559 missense substitutions predicted likely pathogenic (of 1,180 scored), across 118 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D139 | 8 | 0.999 | 0.999 |
| N85 | 8 | 0.998 | 1.000 |
| H128 | 8 | 0.993 | 1.000 |
| N87 | 8 | 0.982 | 0.998 |
| R109 | 7 | 0.994 | 1.000 |
| R15 | 7 | 0.969 | 0.998 |
| E113 | 7 | 0.969 | 0.989 |
| E111 | 7 | 0.963 | 0.994 |
| I81 | 7 | 0.958 | 0.998 |
| M127 | 7 | 0.939 | 0.981 |
| M125 | 7 | 0.920 | 0.979 |
| E114 | 7 | 0.903 | 0.991 |
| H10 | 7 | 0.884 | 0.987 |
| I23 | 7 | 0.883 | 0.997 |
| E22 | 7 | 0.879 | 0.974 |
| Q118 | 7 | 0.840 | 0.999 |
| E151 | 7 | 0.760 | 0.929 |
| E122 | 7 | 0.729 | 0.956 |
| G131 | 6 | 0.999 | 1.000 |
| I146 | 6 | 0.996 | 1.000 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
5 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Liver Hepatocellular Carcinoma (validation) | unfavorable | 2.06e-06 |
| Kidney Chromophobe (TCGA) | unfavorable | 4.71e-05 |
| Liver Hepatocellular Carcinoma (TCGA) | unfavorable | 0.000172 |
| Pancreatic Adenocarcinoma (validation) | unfavorable | 0.000204 |
| Kidney Renal Clear Cell Carcinoma (TCGA) | unfavorable | 0.000211 |
Disease associations
OMIM: gene MIM:607075 | disease phenotypes:
GWAS associations
4 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST006249_62 | Serum metabolite levels | 4e-21 |
| GCST90002397_330 | Mean spheric corpuscular volume | 3e-13 |
| GCST006249_11 | Serum metabolite levels | 4e-11 |
| GCST004730_2 | Facial emotion recognition (sad faces) | 3e-6 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0008329 | facial emotion recognition measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL6067112 (SINGLE PROTEIN)
PharmGKB: 1 entry (CPIC guideline: no)
Binding affinities (BindingDB)
1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.
| Ligand | Measure | Value |
|---|---|---|
| CHEMBL5653589 | KD | 1440 nM |
CTD chemical–gene interactions
34 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Fluorouracil | decreases expression, increases expression | 3 |
| bisphenol A | decreases expression | 2 |
| Aflatoxin B1 | affects cotreatment, decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| triphenyl phosphate | affects expression | 1 |
| pyrogallol 1,3-dimethyl ether | affects cotreatment, decreases expression, affects localization, increases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| ochratoxin A | decreases expression | 1 |
| quinoline | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| bisphenol AF | increases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Caffeine | affects phosphorylation | 1 |
| Choline | affects expression | 1 |
| Doxorubicin | increases expression | 1 |
| Ethyl Methanesulfonate | decreases expression | 1 |
| Formaldehyde | decreases expression | 1 |
| Furaldehyde | affects cotreatment, decreases expression | 1 |
| Ivermectin | decreases expression | 1 |
| Methyl Methanesulfonate | decreases expression | 1 |
| Perfume | increases expression | 1 |
| Progesterone | increases expression | 1 |
| Ribonucleotides | affects binding | 1 |
| Rifampin | decreases expression | 1 |
| Smoke | decreases expression | 1 |
| Sodium Chloride | affects cotreatment, decreases expression, affects localization, increases expression | 1 |
| Tobacco Smoke Pollution | affects expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5651992 | Binding | Binding affinity to human PDAP1 incubated for 45 mins by Kinobead based pull down assay | NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — *ChemMedChem* |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B3DM | Abcam HEK293T PDAP1 KO | Transformed cell line | Female |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Predicted chemistry — Sugi Predict
The predicted patent-compound landscape for PDAP1 across ~30M SureChEMBL compounds — explore on Sugi Predict.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.